Concepts (162)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 40 | 2024 | 5097 | 2.310 |
Why?
|
| Anti-HIV Agents | 17 | 2024 | 1324 | 2.050 |
Why?
|
| Viral Load | 14 | 2023 | 819 | 1.220 |
Why?
|
| Anti-Retroviral Agents | 10 | 2024 | 551 | 1.220 |
Why?
|
| Infectious Disease Transmission, Vertical | 9 | 2024 | 472 | 0.990 |
Why?
|
| Lopinavir | 10 | 2021 | 137 | 0.890 |
Why?
|
| Child | 24 | 2023 | 2242 | 0.800 |
Why?
|
| Nevirapine | 6 | 2019 | 146 | 0.780 |
Why?
|
| Polymerase Chain Reaction | 4 | 2020 | 260 | 0.750 |
Why?
|
| HIV-1 | 7 | 2024 | 1260 | 0.730 |
Why?
|
| Humans | 46 | 2024 | 14537 | 0.720 |
Why?
|
| Bone Density | 6 | 2022 | 107 | 0.720 |
Why?
|
| Benzoxazines | 9 | 2023 | 123 | 0.710 |
Why?
|
| Pregnancy Complications, Infectious | 4 | 2024 | 529 | 0.700 |
Why?
|
| Ritonavir | 8 | 2021 | 137 | 0.670 |
Why?
|
| Female | 36 | 2024 | 9103 | 0.670 |
Why?
|
| Male | 32 | 2024 | 6754 | 0.620 |
Why?
|
| South Africa | 30 | 2024 | 7596 | 0.550 |
Why?
|
| Calcaneus | 3 | 2022 | 14 | 0.510 |
Why?
|
| Immunogenicity, Vaccine | 4 | 2024 | 103 | 0.490 |
Why?
|
| Cohort Studies | 11 | 2021 | 967 | 0.450 |
Why?
|
| Antibodies, Neutralizing | 4 | 2024 | 303 | 0.430 |
Why?
|
| Child, Preschool | 17 | 2019 | 1748 | 0.430 |
Why?
|
| HIV Protease Inhibitors | 3 | 2018 | 92 | 0.420 |
Why?
|
| Vaccines | 2 | 2022 | 86 | 0.370 |
Why?
|
| Infant, Newborn | 9 | 2024 | 1479 | 0.370 |
Why?
|
| Pregnancy | 8 | 2024 | 1862 | 0.340 |
Why?
|
| Antibodies, Viral | 4 | 2024 | 284 | 0.330 |
Why?
|
| Longitudinal Studies | 6 | 2020 | 435 | 0.320 |
Why?
|
| Bone and Bones | 2 | 2020 | 38 | 0.310 |
Why?
|
| Sustained Virologic Response | 2 | 2019 | 22 | 0.300 |
Why?
|
| Alkynes | 8 | 2021 | 117 | 0.290 |
Why?
|
| Cyclopropanes | 8 | 2021 | 123 | 0.290 |
Why?
|
| Lipids | 3 | 2018 | 81 | 0.280 |
Why?
|
| Stavudine | 3 | 2018 | 78 | 0.270 |
Why?
|
| Body Composition | 3 | 2018 | 153 | 0.270 |
Why?
|
| Infant | 10 | 2024 | 2244 | 0.240 |
Why?
|
| Ultrasonography | 3 | 2022 | 77 | 0.220 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2024 | 101 | 0.220 |
Why?
|
| Cross-Sectional Studies | 8 | 2022 | 1422 | 0.220 |
Why?
|
| Case-Control Studies | 6 | 2020 | 480 | 0.210 |
Why?
|
| Microbiota | 1 | 2023 | 30 | 0.210 |
Why?
|
| Dideoxynucleosides | 2 | 2023 | 29 | 0.210 |
Why?
|
| Adolescent | 4 | 2024 | 2985 | 0.200 |
Why?
|
| Adult | 6 | 2024 | 5913 | 0.200 |
Why?
|
| Bone Remodeling | 2 | 2021 | 11 | 0.200 |
Why?
|
| Early Diagnosis | 2 | 2019 | 82 | 0.200 |
Why?
|
| Drug Therapy, Combination | 6 | 2018 | 279 | 0.190 |
Why?
|
| DNA, Viral | 2 | 2022 | 165 | 0.190 |
Why?
|
| Lamivudine | 3 | 2023 | 89 | 0.180 |
Why?
|
| Asymptomatic Infections | 1 | 2020 | 34 | 0.170 |
Why?
|
| Sentinel Surveillance | 1 | 2020 | 115 | 0.170 |
Why?
|
| Treatment Outcome | 6 | 2018 | 889 | 0.170 |
Why?
|
| Mitochondria | 1 | 2019 | 12 | 0.160 |
Why?
|
| DNA, Mitochondrial | 1 | 2019 | 31 | 0.160 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 17 | 0.160 |
Why?
|
| Educational Status | 1 | 2019 | 68 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 71 | 0.160 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 104 | 0.160 |
Why?
|
| Breast Feeding | 1 | 2019 | 120 | 0.150 |
Why?
|
| Drug Substitution | 1 | 2018 | 33 | 0.150 |
Why?
|
| Growth | 1 | 2018 | 14 | 0.150 |
Why?
|
| Aging | 1 | 2018 | 109 | 0.140 |
Why?
|
| Secondary Prevention | 1 | 2017 | 20 | 0.140 |
Why?
|
| Malnutrition | 1 | 2017 | 56 | 0.140 |
Why?
|
| Bone Development | 1 | 2016 | 19 | 0.140 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2017 | 73 | 0.140 |
Why?
|
| Child of Impaired Parents | 1 | 2016 | 9 | 0.140 |
Why?
|
| Body Weights and Measures | 1 | 2016 | 17 | 0.140 |
Why?
|
| Diet | 1 | 2017 | 109 | 0.130 |
Why?
|
| Truth Disclosure | 1 | 2016 | 18 | 0.130 |
Why?
|
| Viremia | 1 | 2016 | 66 | 0.130 |
Why?
|
| Central Nervous System | 1 | 2016 | 11 | 0.130 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2016 | 16 | 0.130 |
Why?
|
| Communication | 1 | 2016 | 57 | 0.130 |
Why?
|
| Vaccination | 3 | 2023 | 365 | 0.130 |
Why?
|
| Absorptiometry, Photon | 3 | 2022 | 85 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 198 | 0.120 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2017 | 472 | 0.110 |
Why?
|
| Exercise | 1 | 2016 | 205 | 0.110 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2012 | 8 | 0.100 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2022 | 60 | 0.100 |
Why?
|
| Immunoglobulin G | 2 | 2024 | 231 | 0.100 |
Why?
|
| T-Lymphocytes | 2 | 2022 | 65 | 0.100 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2018 | 656 | 0.090 |
Why?
|
| Age Factors | 3 | 2018 | 370 | 0.090 |
Why?
|
| Double-Blind Method | 2 | 2021 | 272 | 0.090 |
Why?
|
| Treatment Failure | 2 | 2021 | 175 | 0.080 |
Why?
|
| DNA Methylation | 2 | 2019 | 19 | 0.080 |
Why?
|
| Biomarkers | 2 | 2021 | 327 | 0.080 |
Why?
|
| Growth Disorders | 2 | 2019 | 56 | 0.080 |
Why?
|
| RNA, Viral | 2 | 2019 | 303 | 0.070 |
Why?
|
| Prevalence | 2 | 2022 | 1192 | 0.070 |
Why?
|
| Young Adult | 2 | 2024 | 2498 | 0.060 |
Why?
|
| Anthropometry | 2 | 2018 | 102 | 0.060 |
Why?
|
| Vaccines, Synthetic | 1 | 2024 | 12 | 0.060 |
Why?
|
| Middle Aged | 2 | 2024 | 3601 | 0.060 |
Why?
|
| Time Factors | 2 | 2018 | 507 | 0.060 |
Why?
|
| Tablets | 1 | 2023 | 39 | 0.050 |
Why?
|
| Body Weight | 1 | 2024 | 111 | 0.050 |
Why?
|
| Mouth | 1 | 2023 | 8 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2023 | 18 | 0.050 |
Why?
|
| RNA | 1 | 2023 | 26 | 0.050 |
Why?
|
| Emtricitabine | 1 | 2023 | 78 | 0.050 |
Why?
|
| Child Development | 1 | 2024 | 93 | 0.050 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2023 | 85 | 0.050 |
Why?
|
| Immunity, Humoral | 1 | 2022 | 42 | 0.050 |
Why?
|
| Adenine | 1 | 2023 | 91 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2022 | 109 | 0.050 |
Why?
|
| Pregnant Women | 1 | 2022 | 89 | 0.050 |
Why?
|
| Tenofovir | 1 | 2023 | 171 | 0.050 |
Why?
|
| Cross Reactions | 1 | 2021 | 44 | 0.050 |
Why?
|
| Safety | 1 | 2021 | 34 | 0.050 |
Why?
|
| Vaccine Potency | 1 | 2021 | 16 | 0.050 |
Why?
|
| Adenoviridae | 1 | 2021 | 39 | 0.050 |
Why?
|
| Prospective Studies | 1 | 2024 | 1160 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 52 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 61 | 0.040 |
Why?
|
| Mutation | 1 | 2021 | 306 | 0.040 |
Why?
|
| Research | 1 | 2020 | 65 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 56 | 0.040 |
Why?
|
| CpG Islands | 1 | 2019 | 6 | 0.040 |
Why?
|
| Aged | 1 | 2024 | 1740 | 0.040 |
Why?
|
| Education | 1 | 2019 | 22 | 0.040 |
Why?
|
| HIV Seronegativity | 1 | 2019 | 52 | 0.040 |
Why?
|
| Disease Transmission, Infectious | 1 | 2019 | 39 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2019 | 14 | 0.040 |
Why?
|
| Prenatal Care | 1 | 2020 | 147 | 0.040 |
Why?
|
| Lipodystrophy | 1 | 2018 | 7 | 0.040 |
Why?
|
| Telomere | 1 | 2018 | 17 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2018 | 149 | 0.040 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2018 | 23 | 0.040 |
Why?
|
| Mass Screening | 1 | 2020 | 245 | 0.040 |
Why?
|
| Collagen Type I | 1 | 2018 | 6 | 0.040 |
Why?
|
| Hospitals | 1 | 2018 | 103 | 0.040 |
Why?
|
| Point-of-Care Testing | 1 | 2019 | 71 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2019 | 105 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 150 | 0.040 |
Why?
|
| Peptides | 1 | 2018 | 40 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 296 | 0.040 |
Why?
|
| Diet Surveys | 1 | 2017 | 7 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 163 | 0.040 |
Why?
|
| Nutrition Assessment | 1 | 2017 | 12 | 0.040 |
Why?
|
| Recommended Dietary Allowances | 1 | 2017 | 11 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 385 | 0.040 |
Why?
|
| Mothers | 1 | 2019 | 195 | 0.040 |
Why?
|
| Dyslipidemias | 1 | 2018 | 57 | 0.040 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2018 | 118 | 0.040 |
Why?
|
| Neonatal Screening | 1 | 2017 | 24 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2018 | 132 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 370 | 0.040 |
Why?
|
| Lost to Follow-Up | 1 | 2017 | 62 | 0.040 |
Why?
|
| Self Report | 1 | 2017 | 114 | 0.030 |
Why?
|
| Foot | 1 | 2016 | 5 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2016 | 55 | 0.030 |
Why?
|
| Child Health Services | 1 | 2016 | 35 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2018 | 317 | 0.030 |
Why?
|
| Animals | 1 | 2018 | 1081 | 0.030 |
Why?
|
| Haplotypes | 1 | 2016 | 125 | 0.030 |
Why?
|
| HIV | 1 | 2018 | 380 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2016 | 563 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2012 | 79 | 0.020 |
Why?
|